FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology and immunology. What is presented is a host cell of Bordetella pertussis, Bordetella bronchiseptica or Bordetella parapertussis, which is used as an adjuvant or for preventing or treating whooping cough, having the low activity of endogenous glycosyltransferase at least 98% identical to the amino acid sequence SEQ ID NO: 2 as compared to the activity of glycosyltransferase of a relative parent strain, wherein the low activity is ensured by using an inactivating vector, which causes the inactivation of expression of a sequence of endogenous nucleic acid coding glycosyltransferase, or reduces to a low level of expression of the sequence of endogenous nucleic acid coding glycosyltransferase by the fusion of nucleic acid coding glycosyltransferase with a low-level or inducible promotor. What is disclosed is a preparation consisting of LPS of the above host cell with an increased replacement of hexosamine 1' or 4' phosphate groups of LPS referred to a lipid A, as compared to a LPS preparation from the related parent strain; thereby LPS is characterised by producing at least 8 ions in the ESI-MS spectrum, wherein the preparation is used as an adjuvant or for preventing or treating whooping cough. What is presented is using the above host cells or the LPS preparation for producing the preparation for preventing and/or treating whooping cough, or producing the drug preparation for immunising a mammal, wherein the host cells or LPS is used as an adjuvant. What is described is a pharmaceutical composition used as the adjuvant or for preventing or treating Bordetella infection containing the above host cell or above LPS preparation in an effective amount and a pharmaceutically acceptable carrier.
EFFECT: invention enables producing the pharmaceutical preparation of Bordetella cells or LPS, possessing the high immunogenicity as compared to the preparation of the related parent strain Bordetella.
12 cl, 7 dwg, 3 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
MODIFIED ADENYLATE CYCLASE BORDETELLA CONTAINING CD11b/CD18 INTERACTION DOMAIN OR CD11B/CD18 INTERACTION DOMAIN DEFICIENT, AND ITS APPLICATION | 2004 |
|
RU2421241C2 |
DISHWARE WASHING METHOD | 2007 |
|
RU2509152C2 |
POLYPEPTIDE AND COMPOSITION HAVING XYLANASE ACTIVITY, POLYPEPTIDE APPLICATION, POLYNUCLEOTIDE ENCODING POLYPEPTIDE, EXPRESSION VECTOR CONTAINING POLYNUCLEOTIDE, METHOD FOR PRODUCTION OF POLYNUCLEOTIDE, AND METHOD FOR TREATMENT OF PLANT OR XYLAN-CONTAINING MATERIAL | 2000 |
|
RU2291901C2 |
TALAROMYCES EMERSONII BETA-GLUCANASES | 2001 |
|
RU2321635C2 |
NEW VIRUS OF PLANTS | 2006 |
|
RU2411290C2 |
AGENTS AND METHODS BASED ON USING FIBRONECTIN OF DOMAIN EDA | 2006 |
|
RU2430738C2 |
PROCESS FOR DETERGENT-FREE PRODUCTION OF OUTER MEMBRANE VESICLES OF A GRAM-NEGATIVE BACTERIUM | 2012 |
|
RU2607021C2 |
MUTANT POLYPEPTIDES SUAA AND POLYPEPTIDE DERIVATIVES SUITABLE FOR DELIVERY OF IMMUNOGENIC MOLECULES IN CELL | 2010 |
|
RU2585216C2 |
RAPID SELECTION METHOD FOR HIV GP-120 VARIANTS | 2012 |
|
RU2603732C2 |
IpaD-PROTEIN SHIGELLA AND APPLYING IT AS SHIGELLA INFECTIONS VACCINE | 2007 |
|
RU2450826C2 |
Authors
Dates
2015-02-20—Published
2008-03-25—Filed